

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 87813

Title: Advances and key focus areas in gastric cancer immunotherapy: A comprehensive

scientometric and clinical trial review (1999-2023)

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04700321 Position: Peer Reviewer Academic degree: PhD

Professional title: Associate Professor, N/A

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2023-08-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-08-28 15:11

Reviewer performed review: 2023-09-01 00:04

Review time: 3 Days and 8 Hours

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Overall Review: This paper presents a systematic analysis of the literature and ongoing clinical trials related to immunotherapy for gastric cancer. The authors used scientometric analysis to analyze the relevant literature and identified emerging trends and key focus areas in the field of gastric cancer immunotherapy. The paper provides valuable insights into the current progress and future development trends in this field, as well as scientific research recommendations for researchers. 1. Can you provide more details about the specific methodologies used in the scientometric analysis? How were the literature and clinical trial data collected and analyzed? 2. What were the main findings of the scientometric analysis? Were there any notable trends or patterns identified in the literature and clinical trial data? 3. Can you explain the significance of the identified clusters and keywords, such as TME, MSI, DC, and ACT, in the context of gastric cancer immunotherapy? 4. How do the findings of this analysis contribute to the current understanding of gastric cancer immunotherapy? Are there any novel insights or recommendations for future research? 5. Can you provide more information about the ongoing clinical trials in the field of gastric cancer immunotherapy? What are the specific



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

interventions and endpoints being studied? 6. Are there any limitations or challenges in the current research on gastric cancer immunotherapy that need to be addressed? How can these limitations be overcome in future studies? 7. How do the findings of this analysis align with the existing literature and current clinical practice in the field of gastric cancer immunotherapy? 8. Are there any specific recommendations or implications for clinical practice or policy development based on the findings of this analysis?



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 87813

Title: Advances and key focus areas in gastric cancer immunotherapy: A comprehensive

scientometric and clinical trial review (1999-2023)

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00001114 Position: Editor-in-Chief Academic degree: MD, PhD

Professional title: Chief Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2023-08-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-08-29 03:47

Reviewer performed review: 2023-09-07 11:29

Review time: 9 Days and 7 Hours

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

My comments to Authors: This review includes a literature search on immunotherapy for gastric cancer from 1999 to 2023, along with an analysis of research trends using scientometric methods. While the discussion section elaborates on the specifics of immunotherapy, the primary focus of this study lies in tracking research trends. I believe that delving into the intricacies of immunotherapy would have added considerably to the content, potentially making it difficult for readers to grasp the intent of the study. It is my suggestion that the information could have been presented more succinctly for the reader's understanding. Overall, this review article is well written, and I have noted a few minor comments below: Introduction 1. The abstract states that gastric cancer has the fourth highest cancer mortality rate, while the introduction states that it is the third highest, which is inconsistent. Results 1. In Section 3.1.2, percentages should be reported to the first decimal place. Reference 1. Reference 19: J. Clin. Oncol. 2023, 41,1471-+ should be corrected to J. Clin. Oncol. 2023, 41,1470-1491.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 87813

Title: Advances and key focus areas in gastric cancer immunotherapy: A comprehensive

scientometric and clinical trial review (1999-2023)

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04700321 Position: Peer Reviewer Academic degree: PhD

Professional title: Associate Professor, N/A

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2023-08-28

Reviewer chosen by: Jing-Jie Wang

Reviewer accepted review: 2023-09-26 04:20

Reviewer performed review: 2023-09-26 04:26

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The revised version can be accepted for publication.